The imperative of overcoming barriers to the conduct of large, simple trials

JAMA. 2014 Apr 9;311(14):1397-8. doi: 10.1001/jama.2014.1030.

Authors

Zubin J Eapen¹, Michael S Lauer², Robert J Temple³

Affiliations

¹ Duke Clinical Research Institute, Durham, North Carolina.
² Office of the Director of the Division of Cardiovascular Sciences of the National Heart, Lung, and Blood Institute, Bethesda, Maryland.
³ Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland.

PMID: 24715072
DOI: 10.1001/jama.2014.1030

No abstract available

Publication types

Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, P.H.S.

MeSH terms

Biomarkers
Data Collection / methods
Drug Evaluation / methods
Humans
Precision Medicine
Randomized Controlled Trials as Topic / economics
Randomized Controlled Trials as Topic / methods*
United States
United States Food and Drug Administration

Substances

Biomarkers

Grants and funding

U19FD003800/FD/FDA HHS/United States